The current stock price of NTBL is 0.2479 USD. In the past month the price decreased by -45.4%. In the past year, price decreased by -90.85%.
ChartMill assigns a fundamental rating of 1 / 10 to NTBL. NTBL has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NTBL reported a non-GAAP Earnings per Share(EPS) of -6.91. The EPS increased by 65.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| Debt/Equity | 0.03 |
8 analysts have analysed NTBL and the average price target is 9.18 USD. This implies a price increase of 3603.11% is expected in the next year compared to the current price of 0.2479.
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
NOTABLE LABS LTD
320 Hatch Drive
Foster City CALIFORNIA US
Employees: 16
Phone: 14158512410
Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
The current stock price of NTBL is 0.2479 USD. The price decreased by -27.68% in the last trading session.
NTBL does not pay a dividend.
NTBL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
NOTABLE LABS LTD (NTBL) has a market capitalization of 2.39M USD. This makes NTBL a Nano Cap stock.